Lack of Fas antagonism by Met in human fatty liver disease.
about
MET: a critical player in tumorigenesis and therapeutic targetTargeting Cell Death and Sterile Inflammation Loop for the Treatment of Nonalcoholic SteatohepatitisReceptor tyrosine kinase Met promotes cell survival via kinase-independent maintenance of integrin α3β1A multi-component classifier for nonalcoholic fatty liver disease (NAFLD) based on genomic, proteomic, and phenomic data domains.Adipocyte apoptosis, a link between obesity, insulin resistance, and hepatic steatosis.CD46 protects against chronic obstructive pulmonary disease.The association of PNPLA3 variants with liver enzymes in childhood obesity is driven by the interaction with abdominal fat.Principles of liver regeneration and growth homeostasis.CD95 is part of a let-7/p53/miR-34 regulatory networkExtranodal NK/T-cell lymphoma: toward the identification of clinical molecular targetsAn apoptosis panel for nonalcoholic steatohepatitis diagnosisDeath Receptor-Mediated Cell Death and Proinflammatory Signaling in Nonalcoholic Steatohepatitis.Differential regulation of inflammation and apoptosis in Fas-resistant hepatocyte-specific Bid-deficient miceBeyond insulin resistance: Innate immunity in nonalcoholic steatohepatitis.Tumour-associated macrophages correlate with microvascular bed extension in colorectal cancer patients.Somatic mutation and functional polymorphism of a novel regulatory element in the HGF gene promoter causes its aberrant expression in human breast cancer.Prevention of hepatocarcinogenesis and increased susceptibility to acetaminophen-induced liver failure in transaldolase-deficient mice by N-acetylcysteineHepatocyte-specific NEMO deletion promotes NK/NKT cell- and TRAIL-dependent liver damage.Experimental liver fibrosis research: update on animal models, legal issues and translational aspects.Protective Effect of Met12, a Small Peptide Inhibitor of Fas, on the Retinal Pigment Epithelium and Photoreceptor After Sodium Iodate InjuryApoptosis in nonalcoholic fatty liver disease: diagnostic and therapeutic implications.ASH and NASH.Immunological and molecular basis of nonalcoholic steatohepatitis and nonalcoholic fatty liver disease.Immunoregulation by lipids during the development of non-alcoholic steatohepatitis.Novel Death Defying Domain in Met entraps the active site of caspase-3 and blocks apoptosis in hepatocytes.Lipotoxic lethal and sublethal stress signaling in hepatocytes: relevance to NASH pathogenesis.c-MET receptor tyrosine kinase as a molecular target in advanced hepatocellular carcinoma.The Met protooncogene is a transcriptional target of NF kappaB: implications for cell survival.Inhibition of retinal detachment-induced apoptosis in photoreceptors by a small peptide inhibitor of the fas receptorTIMP3 overexpression in macrophages protects from insulin resistance, adipose inflammation, and nonalcoholic fatty liver disease in mice.Fas cell surface death receptor controls hepatic lipid metabolism by regulating mitochondrial function.Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease.In search of proof-of-concept: gene therapy for glycogen storage disease type Ia.c-Met and Other Cell Surface Molecules: Interaction, Activation and Functional Consequences.
P2860
Q27008925-4DEA5E18-01C1-4DA1-AF66-2CE28EAA7DFBQ28077079-1DE32C59-5966-460E-A714-5275B73AD880Q30791975-54CCEF3B-0D36-42E5-91EB-A5CA2BE4A572Q31171499-CCF0D8F6-1D8B-4ED2-BA46-53020EDBD014Q33661588-D8F90D45-B581-4BF0-B6C6-0E03B6CBA46BQ33900680-0C22FE6E-6330-4B42-85ED-C5EB17F91BDCQ34091146-8772C2F4-44BE-458F-BBBD-C4CEF5233C72Q34347580-EBCC1A1B-6F64-478E-A4AB-9F941B10D330Q34482626-F4A90068-1FB7-417E-8CD2-CBD095EAF1D7Q34898306-4DE294B4-DBB1-404E-A82B-7E8D126366B2Q34995562-B4B95AC5-76FD-45F9-91D6-0391AC958ACBQ35122049-E4C3651D-F38A-4A93-8BD0-B55C0C5A9E17Q36462882-4D1EEF30-C83D-4053-8A6D-245355B6CDAFQ36669223-C062351C-ACBC-4BD6-9275-623781B2C45AQ37056978-69A6E8DF-8FBF-4E34-B0A0-6695A403F5FBQ37111358-0925809F-334F-4884-B6EA-82ADA8222AA0Q37209229-529ADADA-F155-4C2E-B8E9-E391572CB669Q37292795-CD4ABCDE-A2C2-4F4F-B944-7D99B42EAAAAQ37363773-2AD7A0FA-1BB4-41AA-88ED-3B2E6DE6AE28Q37731904-32971C25-EE8F-43AE-BA46-22CD8C1573CDQ37863133-532C1567-155F-45D3-A1DA-DD70F8F4E8C3Q37898415-C6BAB618-41E1-48AD-827C-7F2502F85535Q38131030-B3AEDC03-B465-42E9-BDC5-4B1A0ADD91A1Q38365029-CD3188AA-27E1-4C08-AB66-F0E5753C6B6FQ38616624-893171A7-4F7B-4526-90C8-2CAC7842B790Q38799232-5A17E603-3449-4F06-8191-E6D936DFB2BFQ38923535-7C0D3263-B360-4292-B9EA-2E274CAD064EQ40500532-1C74E83F-7281-455C-B0B4-81A338FBBF27Q40503135-44E84378-E170-4602-8635-78E62A08BD5DQ40666812-9DA4F35B-2AE0-4CCF-9447-6FFBA899B2D9Q41540107-15A195F3-A02E-48DA-B345-C097366FB477Q43107476-778E9EB0-DCEF-47BB-969D-D3DB917D19E6Q45876893-260401F9-B064-433A-A765-F617A197D3BBQ50985108-231073A6-9B20-4ACE-8A03-854515E506AB
P2860
Lack of Fas antagonism by Met in human fatty liver disease.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Lack of Fas antagonism by Met in human fatty liver disease.
@en
type
label
Lack of Fas antagonism by Met in human fatty liver disease.
@en
prefLabel
Lack of Fas antagonism by Met in human fatty liver disease.
@en
P2093
P356
P1433
P1476
Lack of Fas antagonism by Met in human fatty liver disease.
@en
P2093
Amanda E Eaker
Carla J Johnson
Chunbin Zou
George K Michalopoulos
John Stoops
Marie C DeFrances
Reza Zarnegar
P2888
P304
P356
10.1038/NM1625
P407
P577
2007-08-19T00:00:00Z